MD1003

Top 10 Multiple Sclerosis Stories of 2018

Multiple Sclerosis News Today brought you daily coverage of key findings, treatment developments, andĀ clinical trials related to multiple sclerosis (MS) throughout 2018. We look forward to reporting more news to patients, family members, and caregivers dealing with MS during 2019. Here are the top 10 most-read articles of…

Phase 3 Trial of MD1003 in Treating Progressive MS Fully Enrolled, MedDay Announces

A Phase 3 clinical trial intending to confirm the potential ofĀ MD1003, a high-dose biotin, in treating progressive multiple sclerosisĀ (MS) patients is completely enrolled, MedDay Pharmaceuticals, the investigational therapy’s developer, announced. The randomized, double-blind, and placebo-controlled study (NCT02936037), called SPI2, follows the previous Phase 3 trial (NCT02220933),…

#ACTRIMS2018 – MS Therapy MD1003’s Disability Improvements Hold Over Time, Study Shows

MedDay Pharma’sĀ MD1003Ā leads to long-lasting improvements in progressive multiple sclerosis patients’ disability, a Phase 3 clinical trial follow-up study shows. Researchers presented the results at the thirdĀ Annual Americas Committee for Treatment and Research in Multiple Sclerosis ForumĀ in San Diego, Feb. 1-3. The poster presentation was titledĀ ā€œ…

Top 10 Multiple Sclerosis Articles of 2017

Multiple Sclerosis News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other events dealing with multiple sclerosis throughout 2017. We look forward to providing more news to MS patients, family members, and caregivers during 2018. As a reminder of what mattered most to you in…

Using Biotin? It Could Impact Your Lab Results

Be careful if you’re using high-dose biotin (vitamin B7). The biotin in your blood could lead to some false readings when you have that blood tested. The level of concern about this is high enough to warrant aĀ warning from the U.S. Food and Drug Administration. High doses of biotin…

An MS Study You Might Want to Join

I was surprised to see that a study of a potential MS drug labeled MD1003 is still accepting participants. It’s a study that I’d love to take part in, if only I was a few years younger. MD1003 is a high dose of biotin, a form of…

MedDay’s New Phase 3 Trial and Belief in Biotin’s Potential to Treat Progressive MS: An Interview with Dr. FrĆ©dĆ©ric Sedel

A global Phase 3 clinical trial assessingĀ MD1003 ā€” also known as high-dose biotin ā€” for progressive multiple sclerosis (MS) might lead to the approval of one of the first treatmentsĀ helping selectĀ progressive patients to improve. The trial aims to prove that high-dose biotin can reverse disability in non-active progressive MS.

Top 10 Multiple Sclerosis Articles of 2016

A number ofĀ important discoveries, therapeutic developments, and events related to multiple sclerosis (MS) were reported dailyĀ by Multiple Sclerosis News Today throughout 2016. Now that the year is over, it is time to briefly review the articles that appealed most toĀ ourĀ readers. Here are the top 10 most-read articles of 2016, with…

MedDay Presents Phase 3 Extension Data on Potential Drug to Treat Progressive MS

Data from an extension phase of aĀ Phase 3 clinical trial, given in an oral presentation by MedDay, reportedĀ that the biotinĀ Ā MD1003 showedĀ effectiveness over time as a possibleĀ treatment of non-active, progressive multiple sclerosis (MS). The dataĀ were presented atĀ the recentĀ 2nd Congress of the European Academy of Neurology (EAN) in DenmarkĀ byĀ ProfessorĀ Ayman Tourbah,…

MedDayā€™s MD1003, a Biotin, Shows ‘Remarkable’ Efficacy in Treating Inactive but Progressive MS in Clinical Trials

MedDayĀ recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials ofĀ its therapeutic candidate MD1003 in patients with multiple sclerosis (MS). Specifically, the trials included people with “not active”Ā progressive MS and those with either relapsing or progressive MS andĀ visual loss, respectively. Data, presented at the recentĀ American…

MedDay Raises $38.5M to Finance Phase 3 Trial Targeting Progressive MS

MedDay SASĀ recently announced that it has raised ā‚¬34 million, about $38.5 million, in a Series B financing round. The moneyĀ will enable the company to lead a confirmatory Phase 3 clinical trial, called SPI2, in the United StatesĀ toĀ assess itsĀ lead candidate, MD1003, as a treatment for progressive multiple sclerosis (MS). MedDayĀ concluded…

New MS Drug To Be Distributed By Global Supply Chain Distributor Durbin

Medical Need Europe, a privately held pharmaceutical company headquartered in Sweden and focused on registration, distribution, marketing and sale of orphan drugs and niche speciality pharmaceuticals for treatment of rare diseases, has appointed London, U.K. based Durbin PLC, a leading global supplier and distributor of pharmaceuticals, to manage…

Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting

MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective forĀ treatment of progressive multiple sclerosis, according to results from a recent Phase III trial. MD1003 may have two beneficial effects: 1) increasing myelin, the fatty nerve-insulating…